Extracellular vesicle–mediated delivery of miR-181a-3p confers neuroprotection to degenerating retinal ganglion cells

Overview

This research investigates extracellular vesicles (EVs) as a delivery platform for microRNA-181a-3p (miR-181a-3p) to provide neuroprotective effects in retinal ganglion cells (RGCs) experiencing degenerative processes. The study addresses the therapeutic potential of EV-mediated miRNA delivery in glaucoma and related optic neuropathies by establishing EVs as a biocompatible and cell-specific drug delivery vehicle.

Methods and approach

The investigation employed extracellular vesicles as a delivery platform for miR-181a-3p to target degenerating retinal ganglion cells. The approach leverages the inherent biocompatibility and cell-targeting properties of EVs while examining functional efficacy of miRNA-loaded vesicles in neuroprotective applications. The study design assessed both the delivery efficiency and biological outcomes in retinal tissue models relevant to optic neuropathy pathophysiology.

Results

Administration of miR-181a-3p via extracellular vesicles demonstrated neuroprotective efficacy in degenerating retinal ganglion cells. The findings establish that EV-mediated delivery achieves selective cellular uptake in retinal tissues while conferring functional neuroprotective effects. These results indicate that EV-based miRNA delivery represents a viable and effective platform for targeting RGC degeneration.

Implications

The results suggest that EV-mediated miR-181a-3p delivery may constitute a novel therapeutic approach for glaucoma management and treatment of related optic neuropathies characterized by RGC loss. The demonstrated biocompatibility and cell-specificity of the EV platform address critical translational considerations in retinal gene therapy development. This delivery mechanism may enable effective miRNA therapeutics in neurodegenerative ocular diseases where conventional delivery modalities present limitations.